Regeneron Pharmaceuticals, Inc. (LON: 0R2M)

Market Cap	59.41B
Revenue (ttm)	10.33B
Net Income (ttm)	3.47B
Shares Out	n/a
EPS (ttm)	30.16
PE Ratio	17.11
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,700
Average Volume	1,044
Open	690.13
Previous Close	685.67
Day's Range	685.70 - 698.97
52-Week Range	685.70 - 998.57
Beta	n/a
RSI	40.09
Earnings Date	Feb 3, 2025

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 13,450
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R2M

Financial Performance

In 2023, Regeneron Pharmaceuticals's revenue was $13.12 billion, an increase of 7.76% compared to the previous year's $12.17 billion. Earnings were $3.95 billion, a decrease of -8.87%.

Financial numbers in USD